12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RGN-259: Preliminary Phase II data

Preliminary data from a double-blind Phase II trial in 9 patients showed that RGN-259 given 6 times daily for 28 days significantly improved signs and symptoms of severe dry eye, including ocular discomfort and corneal fluorescein staining, at various time points throughout the trial and at 28 days post-treatment vs. vehicle-treated controls....

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >